Saturday, October 3, 2026

GBP/EUR Is 1% Down In The Last 10 Sessions

ViaNews Editorial Team

September 24, 2023

GBP/EUR Is 1% Down In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.34% for the last 10 sessions. At 18:07 EST on Sunday, 24 September, GBP/EUR (GBPEUR) is $1.15.

GBP/EUR's yearly highs and lows, it's 6.27% up from its 52-week low and 2.379% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Eur/usd treading water near 1.0660, hanging near the top of the range. According to FXStreet on Friday, 22 September, "Hourly candles see the EUR/USD trading just south of the 200-hour Simple Moving Average (SMA) near 1.0685.", "The EUR/USD fell to a Friday low of 1.0615 but recovered to the top side near Friday's peak just north of 1.0670."
  • According to FXStreet on Friday, 22 September, "If the EUR/USD breaches itslow of 1.0614, there is a chance it could revisit the March 15 low of 1.0516 before reaching the 2023 bottom of 1.0481 seen on January 6.", "The Euro (EUR) maintains the selling bias unchanged against the US Dollar (USD), motivating EUR/USD to post new six-month lows near 1.0600early on Friday."
  • Eur/usd price analysis: consolidates near six-month low around 1.0650. According to FXStreet on Friday, 22 September, "On the upside, the EUR/USD pair could face a challenge around the 1.0700 psychological level, followed by the 21-day Exponential Moving Average (EMA) at 1.0735.", "However, the momentum observed in the EUR/USD pair suggests a prevailing bearish sentiment in the market, given that the 14-day Relative Strength Index (RSI) continues to stay below the 50 level."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com